Eledon Pharmaceuticals (ELDN) Free Cash Flow (2013 - 2026)

Eledon Pharmaceuticals' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$22.6 million for Q1 2026.

• Quarterly Free Cash Flow fell 40.8% year-over-year to -$22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 26.2% YoY) and the FY2025 annual result came in at -$62.3 million, down 31.88% from the prior year.
• Free Cash Flow was -$22.6 million for Q1 2026 at Eledon Pharmaceuticals, down from -$14.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$4.6 million in Q3 2022 and bottomed at -$22.6 million in Q1 2026.
• A 5-year average of -$11.8 million and a median of -$9.9 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 35.56% — and 2023, when it tumbled 168.02%.
• Eledon Pharmaceuticals' Free Cash Flow stood at -$9.5 million in 2022, then advanced by 3.68% to -$9.1 million in 2023, then slumped by 107.94% to -$19.0 million in 2024, then rose by 25.79% to -$14.1 million in 2025, then sank by 60.47% to -$22.6 million in 2026.
• Business Quant data shows ELDN's Free Cash Flow at -$22.6 million in Q1 2026, -$14.1 million in Q4 2025, and -$14.5 million in Q3 2025.